NCT06703372Completed
Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients
Effectiveness Of Photobiomodulation In Treatment Of Xerostomia In Type Ii Diabetic Patients (A Randomized, Controlled Clinical Trial)
Source: ClinicalTrials.gov · Last updated 25 Nov 2024
Brief summary (registry, in English)
Xerostomia is a major oral health problem that if not recognized and treated can have a significant effect on a patient's quality of life. It leads to difficulties with speech, swallowing and taste alteration. Pathological causes of xerostomia are divided into local and systemic factors. Local factors include smoking, salivary gland diseases and head and neck radiation therapy. Systemic factors include autoimmune diseases as Sjögren syndrome and hormonal disorders as Diabetes Mellitus. Photobiomodulation (PBM) previously known as Low Level Laser Therapy (LLLT) is the application of red and near infra-red light over injuries or lesions to improve wound and soft tissue healing, reduce inflammation and give relief for both acute and chronic pain. It also has grabbed the attention over the last few years as an effective treatment for xerostomia.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 21 Nov 2024
- Start date
- 20 Oct 2022
- Primary completion date
- 1 Aug 2024
- Lead sponsor
- Hams Hamed Abdelrahman
- Diseases
- Type 2 diabetes
- NCT number
- NCT06703372
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 20 Oct 2022 to the primary completion date, 1 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving any drugs that cause hyposalivation.
- Patients receiving chemotherapy and radiotherapy.
Other illness
- Patients with any systemic disease reported to produce hyposalivation (sjogren's syndrome, hepatitis c, rheumatoid arthritis and lupus erythematosus).
Other
- Individuals with skin lesions in the treatment zone to avoid any complications occurring in this area by laser exposure
Who the study is looking for
- Patients with type 2 diabetes mellitus suffering from xerostomia and on oral hypoglycemic drugs.
- Glycated hemoglobin less than 7%.
- Duration of diabetes mellitus not less than 4 years and not more than 8 years
Age in the registry: 25 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Outpatient Clinic of Oral medicine Department, Faculty of Dentistry, Alexandria University, Egypt Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.